Oncology Medical News about Extended lymphadenectomy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis : The Lancet Oncology
The Lancet Oncology - Online First, 10/23/09

Georgiou P et al. – Extended lymphadenectomy does not seem to confer a significant overall cancer-specific advantage, but does seem to be associated with increased urinary and sexual dysfunction.

Methods

Searched Medline, Embase, Ovid, Cochrane Library, and Google Scholar for studies published between 1965 and 2009 that compared extended lymphadenectomy (EL) with standard rectal resection
20 studies, which included 5502 patients from 1 randomised, 3 prospective non-randomised, and 14 retrospective case—control studies published between 1984 and 2009, met our search criteria and were assessed
2577 patients underwent EL and 2925 underwent non-EL for rectal cancer
Random and fixed-effects meta-analytical models were used where indicated, and between-study heterogeneity was assessed
End-points evaluated included peri-operative outcomes, 5-year survival and recurrence rates

Results

Operating time significantly longer in EL group by 76·7 min
Intra-operative blood loss greater in EL group by 536·5 mL
Peri-operative mortality and morbidity similar between two groups
Data from individual studies showed male sexual dysfunction and urinary dysfunction were more prevalent in EL group
No significant differences in 5-year survival (hazard ratio [HR] 1·09, 95% CI 0·78—1·50), 5-year disease-free survival (HR 1·23, 95% CI 0·75—2·03 ), and local (OR 0·83, 95% CI 0·61—1·13) or distant recurrence (OR 0·93, 95% CI 0·72—1·21)

<< Previous
The influence of chemotherapy on bone mineral density,...

Next >>
Phase I trial of vinflunine and pemetrexed in refractory solid...

Colon Interposition After Esophagectomy With Extended Lymphadenectomy for Esophageal Cancer
Annals of Thoracic Surgery, 10/30/09 Relevance Score: 66%

Morphine/naltrexone extended-release capsules (Embeda): Combination of mu-opioid agonist and mu-opioid antagonist approved for the management of moderate-to-severe pain when continuous analgesia is needed for an extended time period
Formulary, 11/02/09 Relevance Score: 45%

Extended-Release Formulations of Antiepileptic Drugs: Rationale and Comparative Value
Epilepsy Currents, 10/30/09 Relevance Score: 45%

Systematic Review: Safety and Efficacy of Extended-Duration Antiviral Chemoprophylaxis Against Pandemic and Seasonal Influenza
Annals of Internal Medicine, 10/06/09 Relevance Score: 45%

Extended family childcare arrangements in a context of AIDS: collapse or adaptation
AIDS Care, 10/05/09 Relevance Score: 44%